Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
The European respiratory journal（2023）
摘要
Ecleralimab significantly attenuated allergen-induced bronchoconstriction and airway inflammation, and was safe in subjects with mild atopic asthma.
更多查看译文
关键词
mild asthma,antibody,ecleralimab,anti-tslp
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要